Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy

Brain

Volumn 125, Issue 11, 2002, Pages 2381-2391

  Ziemssen, Tjalf ^a   Kümpfel, Tania ^a,b   Klinkert, Wolfgang E F ^a   Neuhaus, Oliver ^c   Hohlfeld, Reinhard ^a,b,d  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Altered peptide ligand (APL); Glatiramer acetate; Immunotherapy; Multiple sclerosis; Neuroprotection

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; DNA; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; RNA; T LYMPHOCYTE RECEPTOR;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CONTROLLED STUDY; DEMYELINATING DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 0036845819     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf252     Document Type: Article

References (52)

1. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997; 94: 10821-6.
2. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998; 91: 135-46.
3. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 2000; 97: 11472-7.
4. Allen JE, Maizels RM. Th1-Th2: Reliable paradigm or dangerous dogma? [Review]. Immunol Today 1997; 18: 387-92.
5. Barde YA. Help from within for damaged axons. Nature 1997; 385: 391, 393.
6. Besser M, Wank R. Cutting edge: Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999; 162: 6303-6.
7. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-75.
8. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. [Review]. Annu Rev Neurosci 1995; 18: 223-53.
9. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-7.
10. Crowe PD, Qin Y, Conlon PJ, Antel JP. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000; 48: 758-65.
11. Dayton JS, Lindsten T, Thompson CB, Mitchell BS. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 1994; 152: 984-91.
12. Duda PW, Krieger JI, Schmied MC, Balentine C, Hafler DA. Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate. J Immunol 2000a; 165: 7300-7.
13. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000b; 105: 967-76.
14. Farina C, Then Bergh F, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001; 124: 705-19.
15. Flugel A, Matsumuro K, Neumann H, Klinkert WE, Birnbacher R, Lassmann H, et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: Inhibition of monocyte transendothelial migration. Eur J Immunol 2001; 31: 11-22.
16. Genain CP, Zamvil SS. Specific immunotherapy: One size does not fit all. Nat Med 2000; 6: 1098-100.
17. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274: 2054-7.
18. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 55: 1704-14.
19. Gravel C, Gotz R, Lorrain A, Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat Med 1997; 3: 765-70.
20. Hickey WF. Leukocyte traffic in the central nervous system: The participants and their roles. [Review]. Semin Immunol 1999; 11: 125-37.
21. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis Principles, problems and perspectives. [Review]. Brain 1997; 120: 865-916.
22. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. [Review]. J Neuroimmunol 2000; 107: 161-6.
23. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing Multiple Sclerosis Study Group. Nat Med 2000; 6: 1176-82.
24. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation? J Exp Med 1999; 189: 865-70.
25. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000; 97: 7446-51.
26. Kitze B, Pette M, Rohrbach E, Stadt D, Kappos L, Wekerle H. Myelin-specific T lymphocytes in multiple sclerosis patients and healthy individuals. J Neuroimmunol 1988; 20: 237.
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
28. Lewin GR, Barde YA. Physiology of the neurotrophins. [Review]. Annu Rev Neurosci 1996; 19: 289-317.
29. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th 1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-21.
30. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994; 265: 1107-10.
31. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5: 49-55.
32. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. [Review]. Immunol Today 1996; 17: 138-46.
33. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, et al. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000; 97: 7452-7.
34. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702-8.
35. Nicholson LB, Murtaza A, Hafler BP, Sette A, Kuchroo VK. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc Natl Acad Sci USA 1997; 94: 9279-84.
36. Paul WE, Seder RA. Lymphocyte responses and cytokines. [Review]. Cell 1994; 76: 241-51.
37. Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, Kappos L, et al. Myelin basic protein-specific T lymphocyte lines from multiple sclerosis patients and healthy individuals. Neurology 1990; 40: 1770-6.
38. Qin Y, Zhang DQ, Prat A, Pouly S, Antel J. Characterization of T cell lines derived from glatiramer-acetate treated multiple sclerosis patients. J Neuroimmunol 2000; 108: 201-6.
39. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma. Proc Natl Acad Sci USA 2001; 98: 3398-403.
40. Schwartz M. Physiological approaches to neuroprotection: Boosting of protective autoimmunity. [Review]. Surv Ophthalmol 2001; 45 Suppl 3: S256-60.
41. Sela M. The concept of specific immune treatment against autoimmune diseases. [Review]. Int Rev Immunol 1999; 18: 201-16.
42. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. [Review]. Expert Opin Pharmacother 2001; 2: 1149-65.
43. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75-85.
44. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry, [Review]. Proc Natl Acad Sci USA 1996; 93: 2253-6.
45. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Protection against experimental allergic encephalomyelitis. Nature 1972; 240: 564-6.
46. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996; 64: 209-17.
47. Teitelbaum D, Sela M, Arnon R. Copolymer 1: From the laboratory to FDA, [Review]. Isr J Med Sci 1997; 33: 280-4.
48. Thoenen H. Neurotrophins and neuronal plasticity. [Review]. Science 1995; 270: 593-8.
49. Webb C, Teitelbaum D, Abramsky O, Arnon R, Sela M. Proceedings: Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Isr J Med Sci 1975; 11: 1388.
50. Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci 1986; 9: 271-7.
51. Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature 1992; 360: 753-5.
52. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001; 24: 979-90.